The short version of research peptide fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-08-01 and is reviewed periodically as new material appears.
TB-500 refers to a synthetic peptide fragment derived from the actin-binding region of thymosin beta-4, a protein present in most mammalian cells. The full protein contains forty-three amino acids, while the commonly sold fragment is a much shorter acetylated sequence, often cited as LKKTETQ. The fragment retains part of the actin-binding motif but lacks the remainder of the parent protein. Material sold under this name is usually lyophilized powder intended for laboratory research, and it is not a finished pharmaceutical product.
Proposed activity centers on actin sequestration and on the movement of cells during repair processes. In cell culture and animal models, the fragment has been associated with migration, tube formation, and tissue remodeling. These observations are frequently described as preliminary, because most published work uses rodent or in vitro systems rather than controlled human trials. Whether the short fragment reproduces the effects of the full protein remains an open question, and the relationship between dose, route, and measured outcome is not well characterized.
Several names appear in scientific and commercial contexts for this peptide. The label TB-500 is informal and does not follow standard biochemical nomenclature. Research articles more often describe the compound as a thymosin beta-4 fragment, Tβ4 fragment, or by its sequence Ac-LKKTETQ. Confusing TB-500 with full-length thymosin beta-4 can lead to incorrect assumptions about activity because the fragment lacks the remaining residues of the parent protein. The relationship between fragment and parent protein remains an active area of study.
Regulatory status differs by country, but TB-500 is not an approved pharmaceutical in major jurisdictions. It is commonly sold as a research chemical for laboratory use, which places responsibility for identity and purity on the supplier and the laboratory. Published human data are limited, and most reports involve preclinical models or cell culture. Questions about whether the fragment mimics all actions of thymosin beta-4, and under which conditions, remain open. Independent verification of any material is therefore a practical requirement in research settings.
TB-500 is a synthetic heptapeptide with the sequence Ac-LKKTETQ. It corresponds to a short N-terminal region of thymosin beta-4, a 43-amino-acid protein found in many cell types. The fragment contains an actin-binding motif, which is one reason it appears in laboratory studies of cell migration and cytoskeletal dynamics. TB-500 is not the full-length protein and is produced as a research chemical rather than an approved therapeutic agent. Its molecular weight is approximately 889 Da.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Lyophilized solid as supplied |
| Water solubility | Soluble | Dissolves in aqueous media |
| Typical storage temperature | -20 °C | Dry powder, desiccated, protected from light |
| Typical analytical method | RP-HPLC with mass spectrometry | Purity from peak area; mass for identity |
| Common synonyms | Tβ4 fragment; thymosin beta-4 fragment | Naming varies by supplier and catalogue |
TB-500 is a catalogue name applied to a synthetic peptide related to thymosin beta-4, an actin-binding protein found in most mammalian cells. Suppliers do not use the label consistently: some describe it as the full 43-residue protein, others as a short fragment from the actin-binding region, and others as a related tetrapeptide. Because the name is commercial rather than chemical, two products sold under it may not contain the same molecule. This naming ambiguity is the first point to check in any description of the material.
The most frequently cited identity is a seven-residue fragment with the sequence LKKTETQ, taken from the actin-binding domain of the parent protein. A separate molecule, N-acetyl-seryl-aspartyl-lysyl-proline, often shortened to Ac-SDKP, derives from the same protein's N-terminal region and appears in overlapping literature. Reported molecular masses therefore differ between sources, and a mass value on its own does not establish which fragment is present. Confirmation requires a defined sequence rather than a single number.
Research interest in thymosin beta-4 fragments centres on actin sequestration, cell migration and tissue repair models. Most published work uses cultured cells or animal wound and cardiac preparations, and findings are generally described as preliminary. No fragment of this protein has been approved as a therapeutic product by major regulators. Reviews of the field note inconsistent dosing, delivery routes and outcome measures across studies, which complicates direct comparison. The material is best understood as a laboratory reagent with an active but unresolved research literature.
Lyophilised peptide powders are hygroscopic, and the fragment absorbs atmospheric moisture when a vial is opened at room temperature. Weighing and aliquoting are normally done quickly in a dry environment, and stock solutions are divided into single-use portions before freezing. Repeated freeze-thaw cycles are avoided because they promote aggregation and can shift the measured content of a vial. These practices are general to synthetic peptides rather than unique to this sequence, but they matter more for short chains kept for long periods.
The seven-residue chain carries several polar and charged side chains, so it dissolves readily in water and in aqueous buffers near neutral pH. No cysteine is present, so disulphide formation is not a concern and reducing agents are unnecessary. Dilute ammonium hydroxide or acetonitrile-water mixtures are sometimes used for stock solutions when initial dissolution is slow. Strongly alkaline conditions and prolonged contact with oxidising agents are avoided because they can modify lysine-containing stretches, and haze in solution usually signals incomplete dissolution or aggregated material.
Identity and purity are checked with reversed-phase high-performance liquid chromatography, which separates the target sequence from truncated or deletion analogues, and with mass spectrometry, which confirms the expected molecular mass. Amino acid analysis and peptide mapping give orthogonal confirmation but are used less often outside specialist laboratories. Counter-ion content varies: material purified on trifluoroacetic acid gradients retains trifluoroacetate, and ion exchange can convert the salt form. Residual water and solvent are measured by Karl Fischer titration or thermogravimetric analysis, and any purity figure should be read together with the method used to obtain it.
Research peptides are typically supplied as a white to off-white lyophilised powder in a sealed vial. The dry solid is more stable than a solution and is normally kept refrigerated or frozen until use. Dissolution is usually done in water, phosphate-buffered saline or a similar aqueous medium, depending on the assay. Because the material is hygroscopic and easily contaminated, opening vials in a low-humidity environment and recording the lot number before use are standard laboratory practices.
Once in solution, short peptides are generally less stable than the dry powder, and repeated freeze-thaw cycles are a common cause of loss. Laboratory guidance usually calls for aliquoting on first dissolution and storing aliquots at -20 °C or below, away from light. Adsorption to plastic and glass surfaces can lower measured concentration, particularly at low concentrations, so container material and buffer choice can affect results. Visible cloudiness, colour change or unexpected precipitate is a signal to re-check the material.
Animal work has examined the peptide in models of cardiac injury, skin wounding, and corneal repair, with reported outcomes covering cell migration, inflammatory cell influx, and tissue remodeling. Several of those experiments used the full-length protein or longer fragments instead of the seven-residue sequence, which makes direct comparison between reports difficult. Results are generally described as tissue-dependent, and effect sizes vary considerably across laboratories. Independent replication is uneven, so the overall picture is incomplete rather than settled.
Controlled human trials of the short fragment are scarce. Much of what appears in review articles is extrapolated from animal models or from studies of the parent protein, and literature searches return a larger body of cardiac and ophthalmic work on thymosin beta-4 than on the abbreviated peptide. Regulatory treatment differs by jurisdiction, and in several countries the material is handled as a research chemical rather than an approved therapeutic. Statements about human benefit should be read as provisional.
HClO ⇌ ClO− + H+ Salts of hypochlorous acid are called hypochlorites. One of the best-known hypochlorites is NaClO, the active ingredient in bleach. HClO is a stronger oxidant than chlorine under standard conditions.
The plasma used in an ICP-MS is made by partially ionizing argon gas (Ar → Ar+ + e−). The energy required for this reaction is obtained by pulsing an alternating electric current in load coil that surrounds the plasma torch with a flow of argon gas. After the sample is injected, the plasma's extreme temperature causes the sample to separate into individual atoms (atomization). Next, the plasma ionizes these atoms (M → M+ + e−) so that they can be detected by the mass spectrometer. An inductively coupled plasma (ICP) for spectrometry is sustained in a torch that consists of three concentric tubes, usually made of quartz. The two major designs are the Fassel and Greenfield torches. The end of this torch is placed inside an induction coil supplied with a radio-frequency electric current. A flow of argon gas (usually 14 to 18 liters per minute) is introduced between the two outermost tubes of the torch and an electrical spark is applied for a short time to introduce free electrons into the gas stream. These electrons interact with the radio-frequency magnetic field of the induction coil and are accelerated first in one direction, then the other, as the field changes at high frequency (usually 27.12 MHz or 40 MHz). The accelerated electrons collide with argon atoms, and sometimes a collision causes an argon atom to part with one of its electrons. The released electron is in turn accelerated by the rapidly changing magnetic field.
== Nutritional and dietary properties == Trehalose is rapidly broken down into glucose by the enzyme trehalase, which is present in the brush border of the intestinal mucosa of omnivores (including humans) and herbivores. It causes less of a spike in blood sugar than glucose. Trehalose has about 45% the sweetness of sucrose at concentrations above 22%, but when the concentration is reduced, its sweetness decreases more quickly than that of sucrose, so that a 2.3% solution tastes 6.5 times less sweet as the equivalent sugar solution. It is commonly used in prepared frozen foods, like ice cream, because it lowers the freezing point of foods. Deficiency of trehalase enzyme is unusual in humans, except in the Greenlandic Inuit, where it is present in only 10–15% of the population.
In medicine, treatment that experts agree is appropriate, accepted, and widely used. Health care providers are obligated to provide patients with the best practice. Also called standard therapy or standard of care. (NCI) Bias
Sources: en.wikipedia.org
Also in 1894, the civil parishes within the Wilmslow district were united into a single parish of Wilmslow, and Styal was made a separate parish. On 1 April 1936, the urban district of Wilmslow was enlarged to take in Handforth and Styal. Wilmslow Urban District Council was granted a coat of arms on 21 June 1951. Wilmslow Urban District was abolished in 1974 under the Local Government Act 1972. As part of those reforms, the area had been considered for possible inclusion within Greater Manchester, but it was ultimately decided to place it in the borough of Macclesfield. No successor parish was created for the former urban district and so it became unparished, being directly administered by Macclesfield Borough Council. In 2009, Cheshire East Council was created, taking over the functions of the borough council and Cheshire County Council, which were both abolished. In 2011, the area of the former Wilmslow Urban District was split into three new parishes called Wilmslow, Handforth, and Styal.
It separately killed Davoud Alizadeh, the commander of the Quds Force's Lebanon Corps, in Tehran. In the night, Hezbollah fired rockets at Tel Aviv and Haifa. By 4 March, more than 300,000 southern Lebanese residents had been displaced due to the conflict. Israeli strikes hit residential areas in Beirut and eastern Lebanon, killing at least 11 people. Two Israeli soldiers were wounded in Lebanon after Hezbollah claimed to have struck a Merkava tank in Houla. On 6 March, a Hezbollah rocket strike in northern Israel injured eight soldiers, five seriously. Later that night, Israeli commandos raided Al-Nabi Shayth in an attempt to recover the remains of missing pilot Ron Arad, leading to a gunbattle that left three Lebanese soldiers dead. Simultaneous airstrikes in the area killed 41 people and injured 40 more. The Israelis withdrew without finding Arad's body. On 8 March, two Israeli soldiers were killed in a separate rocket attack in southern Lebanon. The following day, Hezbollah missiles struck a satellite communications center near Beit Shemesh and a daycare in Ramla in central Israel. On 1 April, an Israeli naval strike in Beirut killed Haj Youssef Ismail Hashem, the commander of Hezbollah's Southern Front. On 8 April, Israeli strikes killed 254 people and wounded more than 1,000 others in central Beirut. Israel Katz said that the strikes targeted hundreds of Hezbollah militants and command centers across Lebanon, in the group's largest blow since the pager attacks. On 16 April, President Trump announced that Israel and Lebanon agreed to a 10-day truce.
Tight junctions are very important in embryo development. In the blastula, these cadherin mediated cell interactions are essential to development of epithelium which are most important to paracellular transport, maintenance of cell polarity and the creation of a permeability seal to regulate blastocoel formation. These tight junctions arise after the polarity of epithelial cells is established which sets the foundation for further development and specification. Within the blastula, inner blastomeres are generally non-polar while epithelial cells demonstrate polarity. Mammalian embryos undergo compaction around the 8-cell stage where E-cadherins as well as alpha and beta catenins are expressed. This process makes a ball of embryonic cells which are capable of interacting, rather than a group of diffuse and undifferentiated cells. E-cadherin adhesion defines the apico-basal axis in the developing embryo and turns the embryo from an indistinct ball of cells to a more polarized phenotype which sets the stage for further development into a fully formed blastocyst. Xenopus membrane polarity is established with the first cell cleavage. Amphibian EP-cadherin and XB/U cadherin perform a similar role as E-cadherin in mammals establishing blastomere polarity and solidifying cell-cell interactions which are crucial for further development.
Sources: en.wikipedia.org
=== Dynamics of surfactants at interfaces === The dynamics of surfactant adsorption is of great importance for practical applications such as in foaming, emulsifying or coating processes, where bubbles or drops are rapidly generated and need to be stabilized. The dynamics of absorption depend on the diffusion coefficient of the surfactant. As the interface is created, the adsorption is limited by the diffusion of the surfactant to the interface. In some cases, there can exist an energetic barrier to adsorption or desorption of the surfactant. If such a barrier limits the adsorption rate, the dynamics are said to be ‘kinetically limited'. Such energy barriers can be due to steric or electrostatic repulsions. The surface rheology of surfactant layers, including the elasticity and viscosity of the layer, play an important role in the stability of foams and emulsions.
== Overview == When an elastic material is deformed due to an external force, it experiences internal resistance to the deformation so that it is restored to its original state if the external force is no longer applied. There are various elastic moduli, such as Young's modulus, the shear modulus, and the bulk modulus, all of which are measures of the inherent elastic properties of a material as a resistance to deformation under an applied load. The various moduli each apply to different kinds of deformation. For instance, Young's modulus applies to extension or ←compression of a body, whereas the shear modulus applies to its shear. Young's modulus and shear modulus only apply to solids, whereas the bulk modulus applies to solids, liquids, and gases. The elasticity of materials is described by a stress–strain curve, which shows the relation between stress (the average restorative internal force per unit area) and strain (the relative deformation). The curve is generally nonlinear, but it can (by use of a Taylor series) be approximated as linear for sufficiently small deformations (in which higher-order terms are negligible). If the material is isotropic, the linearized stress–strain relationship is called Hooke's law, which is often presumed to apply up to the elastic limit for most metals or crystalline materials whereas nonlinear elasticity is generally required to model large deformations of rubbery materials even in the elastic range.
Plasma renin activity (PRA), also known as the renin (active) assay or random plasma renin, is a measure of the activity of the plasma enzyme renin, which plays a major role in the body's regulation of blood pressure, thirst, and urine output. Measure of direct renin concentration (DRC) is technically more demanding, and hence PRA is used instead. DRC assays are still in evolution, and generally a conversion factor of PRA (ng/mL/h) to DRC (mU/L) is 8.2. A recently developed and already commonly used automated DRC assay uses the conversion factor of 12. PRA is sometimes measured, specially in case of certain diseases which present with hypertension or hypotension. PRA is also raised in certain tumors. A PRA measurement may be compared to a plasma aldosterone concentration as an aldosterone-to-renin ratio (ARR).
Sources: en.wikipedia.org
TB-500 is a name used for a short synthetic peptide fragment taken from the actin-binding region of thymosin beta-4. Material sold under this label is usually a lyophilized powder supplied for laboratory research rather than a licensed medicine. The commonly cited sequence is LKKTETQ.
The parent protein contains forty-three amino acids, while the fragment carries only a short motif from one region. The fragment can interact with actin in vitro, but it does not include the rest of the protein structure. Whether the shorter molecule behaves the same way in living systems is not settled.
Published controlled human studies are scarce, and most activity reports come from cell culture or animal models. Reviews often describe the evidence base as limited and methodologically uneven. Open questions include the relationship between route, dose, and measured outcomes.
TB-500 is a synthetic heptapeptide corresponding to a fragment of thymosin beta-4. It is used in laboratory research and is not an approved drug.